BUZZ-H.C. Wainwright starts coverage of Artiva Biotherapeutics with 'buy' rating

Reuters2024-12-30
BUZZ-H<a href="https://laohu8.com/S/02403">.C</a>. Wainwright starts coverage of Artiva Biotherapeutics with 'buy' rating

** Brokerage H.C. Wainwright starts coverage of drug developer Artiva Biotherapeutics ARTV.O with "buy" rating and PT of $20

** PT represents an ~88% upside to stock's last close

** Co is testing its experimental drug, AlloNK, for an autoimmune disease called systemic lupus erythematosus $(SLE)$ in combination with antibodies Rituxan or Gazyva

** SLE is a condition where the immune system attacks the body's own tissues

** Brokerage notes "current treatment options do not effectively control disease progression"

** Says AlloNK costs less than $6,000 per patient for ARTV to produce, compared to ~$100,000 for auto-CAR T therapies

** Co has capacity to produce enough AlloNK for over 1,000 autoimmune patients annually, H.C. Wainwright says

** Brokerage expects AlloNK to launch by 2029 and forecasts sales to grow to $531 mln by 2031

** As of last close, stock has fallen ~34% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment